BriaCell Therapeutics (TSE:BCT) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
BriaCell Therapeutics has announced promising results from their Phase 2 clinical trial, showcasing improved overall survival rates for metastatic breast cancer patients treated with their Bria-IMT™ combination therapy. The therapy demonstrated significant clinical benefits across various breast cancer subtypes, suggesting potential advancements in treatment options for this challenging condition.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
